PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

Press Release
Written by Jamison Wright

https://news.puretechhealth.com/news-releases/news-release-details/puretechs-deupirfenidone-lyt-100-demonstrates-strong-and-durable

Jamison Wright https://jamisonwright.com
Previous

PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases
Next

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)